New unit for rare diseases R&D launched
GlaxoSmithKline (GSK) has launched a standalone unit that will specialize in the R&D and commercialization of medicines for rare diseases.
GlaxoSmithKline (GSK) has launched a standalone unit that will specialize in the R&D and commercialization of medicines for rare diseases. The operation, which will be led by Marc Dunoyer, GSK's President of Asia Pacific and Chairman of Japan, will seek to "leverage existing capabilities and partnerships, and further establish in-licensing opportunities," according to a company press statement.
"In addition to our existing discovery effort, alternative opportunities need to be explored to make treatments available for rare diseases," Dunoyer said in the press statement. "This complimentary approach will combine our existing global expertise with specialist partners. Over time, this new unit has the potential to deliver multiple therapies responding to high medical needs of underserved populations of patients."
In 2009, GSK entered into collaborations with Prosensa (The Netherlands) and JCR Pharmaceuticals (Japan), which both focus on therapeutics that could be used to treat orphan diseases.
"The entry into this new therapeutic area forms part of our strategy to deliver more products of value and improve returns in R&D through a focus on areas with a higher probability of success," Patrick Vallance, GSK's Senior Vice President of Drug Discovery, explained in the press statement. "The risk associated with product discovery and development in rare diseases is generally lower than other disease areas as disease definitions are very clear and clinical trials tend to be small with robust endpoints. In most cases the molecular target is known, making it easier for specialized physicians to diagnose patients”.
According to GSK, more than 5500 rare diseases have been identified, but less than 10% are currently being treated.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
